Search | Clinical Trials Finder

Conditions: Pain, Postoperative, Opioid Use
Interventions: Acetaminophen; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 90 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Health
Interventions: Orange juice, Placebo juice (SunnyD); Other
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Kidney Disease
Interventions: OJR520, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Sarcoidosis
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Birmingham, Alabama • Albany, New York • Cleveland, Ohio

Conditions: Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions: ATI-045, Placebo; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more

Conditions: Hypertension
Interventions: Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 33
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 30 more

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: Osteoarthritis, Knee, Osteoarthritis of the Knee
Interventions: Placebo, Cannabidiol (CBD), Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol); Drug
Lead sponsor: Steven E Harte, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: ADHD - Inattentive Type, ADHD - Combined Type
Interventions: OROS-Methylphenidate and placebo for inattentive type pts, OROS-Methylphenidate and placebo for combined type pts; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 7 Years to 11 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions: XXB750, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Inverness, Florida • Jacksonville, Florida • Saint Paul, Minnesota

Conditions: Knee Osteoarthritis
Interventions: canakinumab, LNA043, Placebo to canakinumab; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more

Conditions: Anxiety
Interventions: Midomafetamine HCl, Placebo, Therapy; Drug · Behavioral
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Anselmo, California

Conditions: COVID-19
Interventions: Baricitinib, Dexamethasone, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 61
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more

Conditions: Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions: pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF; Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Orlando, Florida • Durham, North Carolina

Conditions: Chronic Inflammation, Inflammaging
Interventions: Dietary supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Edifice Health; Industry
Eligibility: 18 Years and older
Enrollment: 781 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Greenbrae, California • Suwanee, Georgia

Conditions: Pain
Interventions: Preservative Free Lidocaine, Saline; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 7 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Femara, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: CY6463, Placebo; Drug
Lead sponsor: Tisento Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Prion Disease
Interventions: ION717, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio

Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions: Mitapivat, Mitapivat-matching placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Graft-versus-Host Disease, Immune System Disorders
Interventions: Mycophenolate Mofetil, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Duarte, California • La Jolla, California • Stanford, California + 28 more

Conditions: Fibromyalgia
Interventions: Sodium Oxybate, Sodium Oxybate & 6 Tablets, Sodium Oxybate & 8 Tablets, Sodium Oxybate Oral Solution (6 grams); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 32
States / cities: Phoenix, Arizona • Anaheim, California • Fair Oaks, California + 26 more

Conditions: Adult Congenital Heart Disease, Heart Failure
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: Anita Saraf; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Carcinoma, Hepatocellular
Interventions: Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE; Drug · Biological · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more

Search by objective public record fields.

IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty

Effects of 100% Orange Juice on Skin Health in Women

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Attention Deficit Disorder Medication Response Study

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

2021 PMT iAge® Intervention Trial by Edifice Health

The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast:

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)